A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
City of Hope Medical Center
M.D. Anderson Cancer Center
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Baylor College of Medicine
M.D. Anderson Cancer Center